Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top 10 Correlated ETFs

MIST


Top 10 Correlated Stocks

MIST


In the News

07:00 25 Sep 2022 MIST

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

MONTREAL and CHARLOTTE, N.C., Nov. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences: The 2021 Jefferies London Virtual Healthcare Conference.

07:00 25 Sep 2022 MIST

Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

MONTREAL and CHARLOTTE, N.C., Sept. 22, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Amit Hasija, Chief Financial Officer and Executive Vice President of Corporate Development, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 10:00 a.m.

04:18 25 Sep 2022 MIST

Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update

MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update.

07:00 25 Sep 2022 MIST

Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM ET.

11:15 25 Sep 2022 MIST

Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.

07:02 25 Sep 2022 MIST

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21

- Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial - - Data Presented at the American College of Cardiology's 70th Annual Scientific Session - MONTREAL and Charlotte, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the presentation of data related to key secondary endpoints from its Phase 3, multicenter, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the Company's novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).

07:01 25 Sep 2022 MIST

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update

MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update.

07:00 25 Sep 2022 MIST

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China

MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions in Greater China.

11:59 25 Sep 2022 MIST

Milestone Pharmaceuticals Stock Is a Bet On Etripamil

If Milestone Pharmaceuticals' Etripamil nasal spray succeeds in clinical trials, MIST stock is going to see big growth. The post Milestone Pharmaceuticals Stock Is a Bet On Etripamil appeared first on InvestorPlace.

05:32 25 Sep 2022 MIST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a clinical and corporate update.

Financial details

Company Rating
Neutral
Market Cap
269.8M
Income
-61.76M
Revenue
15M
Book val./share
2.05
Cash/share
2.04
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
10 Nov 2022
P/E
-5.41
Forward P/E
-
PEG
3.84
P/S
22.29
P/B
3.86
P/C
3.88
P/FCF
-6.71
Quick Ratio
20.45
Current Ratio
21.26
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-1.46
EPS next Y
-
EPS next Q
-
EPS this Y
-14.1%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
18.18%
-
-
-
-
SMA20
17.2%
SMA50
44.3%
SMA100
32.24%
Inst Own
50.45%
Inst Trans
-0.53%
ROA
-68%
ROE
-58%
ROC
-0.71%
Gross Margin
100%
Oper. Margin
-414%
Profit Margin
-412%
Payout
-
Shs Outstand
30.01M
Shs Float
14M
-
-
-
-
Target Price
10
52W Range
3.98-9.7
52W High
-12.11%
52W Low
+163.67%
RSI
43.67
Rel Volume
0.48
Avg Volume
206.81K
Volume
99.27K
Perf Week
-13.27%
Perf Month
13.32%
Perf Quarter
15.47%
Perf Half Y
35.91%
-
-
-
-
Beta
2.65183
-
-
Volatility
0.5%, 0.76%
Prev Close
-5.16%
Price
7.91
Change
-8.13%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2019-12-312020-12-31 2021-12-31
Revenue per share
000.51
Net income per share
-3.5-1.7-1.46
Operating cash flow per share
-3.24-1.73-1.13
Free cash flow per share
-3.27-1.73-1.13
Cash per share
7.594.853.89
Book value per share
7.284.883.84
Tangible book value per share
7.284.883.84
Share holders equity per share
7.284.883.84
Interest debt per share
00.010.03
Market cap
347.26M216.57M206.3M
Enterprise value
227.45M144.5M92.85M
P/E ratio
-6.29-4.33-4.81
Price to sales ratio
0013.75
POCF ratio
-6.79-4.27-6.21
PFCF ratio
-6.73-4.27-6.21
P/B Ratio
3.021.511.83
PTB ratio
3.021.511.83
EV to sales
006.19
Enterprise value over EBITDA
-3.93-2.86-2.18
EV to operating cash flow
-4.45-2.85-2.79
EV to free cash flow
-4.41-2.85-2.79
Earnings yield
-0.16-0.23-0.21
Free cash flow yield
-0.15-0.23-0.16
Debt to equity
000
Debt to assets
0.070.050.06
Net debt to EBITDA
2.071.422.67
Current ratio
14.7124.1417.55
Interest coverage
00-195.79
Income quality
0.931.020.78
Dividend Yield
000
Payout ratio
000
Sales general and administrative to revenue
000.83
Research and developement to revenue
002.58
Intangibles to total assets
000
Capex to operating cash flow
0.0100
Capex to revenue
000
Capex to depreciation
-10.8710
Stock based compensation to revenue
000.49
Graham number
23.9413.6711.23
ROIC
-0.5-0.35-0.38
Return on tangible assets
-0.45-0.33-0.36
Graham Net
7.094.643.65
Working capital
114.17M142.53M112.15M
Tangible asset value
000
Net current asset value
113.99M141.83M111.67M
Invested capital
000.01
Average receivables
892K948K715.5K
Average payables
4.51M4.64M4.51M
Average inventory
000
Days sales outstanding
0011.75
Days payables outstanding
000
Days of inventory on hand
000
Receivables turnover
0031.06
Payables turnover
000
Inventory turnover
000
ROE
-0.48-0.35-0.38
Capex per share
-0.0300

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
0.3600.3600
Net income per share
0.02-0.34-0.4-0.33-0.39
Operating cash flow per share
0.02-0.22-0.29-0.33-0.33
Free cash flow per share
0.02-0.22-0.29-0.33-0.33
Cash per share
3.2632.712.372.04
Book value per share
3.353.022.672.392.05
Tangible book value per share
3.353.022.672.392.05
Share holders equity per share
3.353.022.672.392.05
Interest debt per share
0.020.020.020.020.02
Market cap
229.2M240.86M276.3M271.2M260.01M
Enterprise value
132.24M130.2M162.85M179.59M197.33M
P/E ratio
74.42-4.23-4.09-4.84-3.9
Price to sales ratio
15.28018.4200
POCF ratio
225.82-25.65-22.32-19.44-18.46
PFCF ratio
225.82-25.65-22.32-19.44-18.38
P/B Ratio
1.641.892.452.693
PTB ratio
1.641.892.452.693
EV to sales
8.82010.8600
Enterprise value over EBITDA
166.76-9.14-9.68-12.81-11.76
EV to operating cash flow
130.29-13.86-13.16-12.87-14.01
EV to free cash flow
130.29-13.86-13.16-12.87-13.95
Earnings yield
0-0.06-0.06-0.05-0.06
Free cash flow yield
0-0.04-0.04-0.05-0.05
Debt to equity
00000
Debt to assets
0.040.050.060.050.05
Net debt to EBITDA
-122.277.776.746.533.74
Current ratio
27.122.7117.5522.7721.26
Interest coverage
00-497.59-351.18-106.37
Income quality
1.320.660.7310.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.200.2500
Research and developement to revenue
0.6300.7300
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0000-2.46
Stock based compensation to revenue
0.1300.1300
Graham number
1.184.794.94.224.26
ROIC
0.01-0.11-0.15-0.14-0.19
Return on tangible assets
0.01-0.11-0.14-0.13-0.18
Graham Net
3.142.852.542.271.94
Working capital
139.06M126.91M112.15M100.36M86.25M
Tangible asset value
00000
Net current asset value
138.49M126.4M111.67M99.92M85.86M
Invested capital
0.010.010.010.010.01
Average receivables
901K510.5K570K657K728.5K
Average payables
3.47M3.63M3.72M3.06M2.28M
Average inventory
00000
Days sales outstanding
6.8702.900
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
13.1031.0600
Payables turnover
00000
Inventory turnover
00000
ROE
0.01-0.11-0.15-0.14-0.19
Capex per share
00000

Frequently Asked Questions

What is Milestone Pharmaceuticals Inc. stock symbol ?

Milestone Pharmaceuticals Inc. is a CA stock , located in Saint-laurent of Quebec and trading under the symbol MIST

Is Milestone Pharmaceuticals Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $10. The lowest prediction is $10 and the highest is $10

What is MIST stock prediction ?